中科生物(01237.HK)：预计上半年扭亏为盈至约900万元

Group 1 - The company, Zhongke Biological (01237.HK), expects to record a net profit attributable to shareholders of approximately RMB 9 million in the first half of 2025, compared to a net loss of RMB 1.7 million in the same period of 2024 [1] - The turnaround to profitability is primarily attributed to a foreign exchange gain of approximately RMB 16 million recognized for the six months ending June 30, 2024 [1]